Ira Studin, PhD

Potential for quality equivalent to economies of scale.

Emerging limits of one-year payer time frames.

Initial coverage discussions put the focus on three key factors.

A business framework for pricing and broader brand strategy.

Writing at the intersection of managed markets and the pharmaceutical industry.

How biopharma manufacturers can address extreme pricing of novel rare disease medicines and build legitimacy into commercialization to avoid an industrywide crisis.